Abbott’s landmark publication in The New England Journal of Medicine showcases a promising alternative in the treatment of chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease.
The use of an everolimus-eluting resorbable scaffold was superior to angioplasty with respect to the primary efficacy endpoint.
Scaffold Group: 74% success
Angioplasty Group: 44% success
One-sided P<0.001 for superiority
eKare is immensely grateful to have supported this groundbreaking study related to wound assessment measures alongside the Abbot and Syntropic teams.
Access the article here: https://www.nejm.org/doi/full/10.1056/NEJMoa2305637
